SCHEMBL4060633

SCHEMBL4060633

FC(F)(F)c1ccc(/C=C/c2nc3cc(-c4ccco4)ccc3o2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3R1 P27986 2/20 0.44
PIK3CA P42336 2/20 0.44
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
PGR P06401 1/20 0.38
ERBB2 P04626 8/20 0.38
CCNE2 O96020 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4060638 1.00 PIK3R1 (0.44) PIK3R1PIK3CAALDH1A1MEN1KMT2A
SCHEMBL4054515 0.91 PIK3R1 (0.44) PIK3R1PIK3CAALDH1A1MEN1KMT2A
SCHEMBL4054518 0.91 PIK3R1 (0.44) PIK3R1PIK3CAALDH1A1MEN1KMT2A
SCHEMBL4053714 0.86 HPGD (0.49) PIK3R1PIK3CAALDH1A1MEN1KMT2A
SCHEMBL4053716 0.86 HPGD (0.49) PIK3R1PIK3CAALDH1A1MEN1KMT2A
SCHEMBL4054741 0.85 HPGD (0.51) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL4054737 0.85 HPGD (0.51) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL4062715 0.85 KMT2A (0.44) PIK3R1PIK3CAALDH1A1MEN1KMT2A
SCHEMBL4062709 0.85 KMT2A (0.44) PIK3R1PIK3CAALDH1A1MEN1KMT2A
SCHEMBL4053426 0.84 MEN1 (0.58) ALDH1A1MEN1KMT2ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B PIK3R1 565/4885PIK3CA 848/4885ALDH1A1 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.